GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.

ligufalimab   Click here for help

GtoPdb Ligand ID: 13887

Synonyms: AK-117 | AK117
Immunopharmacology Ligand
Compound class: Antibody
Comment: Ligufalimab (AK117) is a humanized IgG4 anti-CD47 antibody [1-2]. In the tumour microenvironment blocking CD47 interaction with its receptor SIRPα enhances M2 macrophage-mediated phagocytosis of CD47-expressing malignant cells from variety of tumour types. Unlike other anti-CD47 antibodies (such as magrolimab) ligufalimab does not induce hemagglutination, so should be devoid of hematotoxic side effects (anemia and thrombocytopenia) due to the expression of CD47 on erythrocytes.
Click here for help

Ligand Activity Visualisation Charts

These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.

✖

View interactive charts of activity data across species
No information available.
Summary of Clinical Use Click here for help
Ligufalimab (AK117) is a clinical candidate immuno-oncology agent for solid tumours and haematological malignancies.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT06642792 A Study of AK129 With or Without AK117 in PD(L)1-refractory Classic Hodgkin Lymphoma Phase 1/Phase 2 Interventional Akeso
NCT06789848 Ligufalimab and Cadonilimab in Advanced Liver Cancers Phase 2 Interventional University of Texas Southwestern Medical Center
NCT06601335 A Phase 3 Study of AK112 Plus AK117 Versus Pembrolizumab in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) Phase 3 Interventional Akeso
NCT05382442 A Study of AK112 With or Without AK117 in Metastatic Colorectal Cancer Phase 2 Interventional Akeso
NCT05960955 Cadonilimab Combination With Chemotherapy With or Without AK117 in Resectable Gastric or Gastroesophageal Junction Adenocarcinoma Phase 2 Interventional Akeso
NCT06196203 A Study of AK117 in Combination With Azacitidine in Patients With Myelodysplastic Syndromes Phase 2 Interventional Akeso